Bone marrow aplasia with prominent atypical plasmacytic proliferation preceding acute lymphoblastic leukemia.

abstract：:When lymph node biopsies of lymphocytic neoplasms are studied with subtle morphological and immunohistochemical methods meaningful information is obtained, that is not only of theoretical value, but which also relates to the clinical behavior ("leukemia," paraproteinemia, prognosis). Such an analysis allows us to diff...

journal_title：Leukemia & lymphoma

authors： Lennert K,Tamm I,Wacker HH

更新日期：1991-01-01 00:00:00

abstract：:Bone marrow mesenchymal stromal cells (MSCs) can rescue acute lymphoblastic leukemia (ALL) cells from L-asparaginase by replenishing the depleted asparagine. As both vincristine (VCR) and imatinib mesylate (IM) can inhibit MSCs' proliferation, we hypothesized that these drugs might reduce the niche support of MSCs to ...

journal_title：Leukemia & lymphoma

authors： Fung KL,Liang RH,Chan GC

更新日期：2010-03-01 00:00:00

abstract：:Patients with early stage favorable Hodgkin's disease who relapse after extended field radiotherapy have satisfactory results. We retrospectively analysed patients with relapsed HD after initial radiation therapy alone to determine treatment outcome and prognostic factors. Nine-hundred and forty five patients in local...

journal_title：Leukemia & lymphoma

authors： Rüffer JU,Ballova V,Glossmann J,Sieber M,Franklin J,Nogova L,Diehl V,Josting A,German Hodgkin Study Group.

更新日期：2005-11-01 00:00:00

abstract：:The European Society for Blood and Marrow Transplantation Chronic Malignancies Working Party held a preceptorship meeting in Turin, Italy on 25-26 September 2014, to discuss the role of stem cell transplantation (SCT) in the treatment of multiple myeloma and other plasma cell disorders. Scientists and clinicians worki...

journal_title：Leukemia & lymphoma

authors： Bruno B,Auner HW,Gahrton G,Garderet L,Festuccia M,Ladetto M,Lemoli RM,Massaia M,Morris C,Palumbo A,Schönland S,Boccadoro M,Kröger N

更新日期：2016-01-01 00:00:00

abstract：:The adenosine deaminase inhibitor 2'-deoxycoformycin (dCF) significantly inhibits the proliferation of leukemia and lymphoma cells in the presence of either 2'-deoxyadenosine (dAdo) or its analog adenine arabinoside (araA). The concentration of dCF required to induce apoptosis of monocytoid leukemia cells is much lowe...

journal_title：Leukemia & lymphoma

authors： Honma Y

更新日期：2001-09-01 00:00:00

abstract：:We retrospectively examined the results of a new chemo-free approach combining blinatumomab with ponatinib (blina/pona) in 26 relapsed/refractory Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patients. All but one achieved complete morphologic remission, and 23 achieved a complete molecular response. ...

journal_title：Leukemia & lymphoma

authors： Couturier MA,Thomas X,Raffoux E,Huguet F,Berthon C,Simand C,Gallego-Hernanz MP,Hicheri Y,Hunault Berger M,Saillard C,Leguay T,Loiseau C,Béné MC,Chevallier P

更新日期：2020-11-06 00:00:00

abstract：:Phosphorylation of p27(Kip1) at threonine 187 (pThr187-p27(Kip1)) occurs frequently in the development of human tumors, directing protein polyubiquitination and subsequent proteasomal degradation. We investigated the immunoexpression of p27(Kip1) and pThr187-p27(Kip1) in 126 B-cell lymphomas and their relation to prol...

journal_title：Leukemia & lymphoma

authors： Sirinian C,Symeonidis A,Giannakoulas N,Zolota V,Melachrinou M

更新日期：2011-05-01 00:00:00

abstract：:Granulocyte-colony stimulating factors (G-CSFs) enhance bone marrow (BM) recovery after autologous stem cell transplant (ASCT) in patients with lymphoma and myeloma. Few publications exist that discuss the use of filgrastim biosimilars after ASCT. We conducted a single-center retrospective study in patients with lymph...

journal_title：Leukemia & lymphoma

authors： Ianotto JC,Ngo Sack F,Couturier MA,Tempescul A,Mugnier N,Delepine P,Guillerm G,Berthou C

更新日期：2014-01-01 00:00:00

abstract：:We investigated 41 diffuse large B-cell lymphomas (DLBCL) diagnosed at one center harboring ≥50% of latently Epstein-Barr virus (EBV)-infected neoplastic cells occurring in 34 patients aged ≥50 years and in 7 patients younger than 50 years in the absence of any known immunodeficiency for the expression patterns of EBV...

journal_title：Leukemia & lymphoma

authors： Jöhrens K,Trappe RU,Lenze D,Pfreundschuh M,Ziepert M,Hummel M,Anagnostopoulos I

更新日期：2016-12-01 00:00:00

abstract：:We describe the patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for the initial staging of patients with newly diagnosed grade 1-2 follicular lymphoma (FL) and its potential impact on treatment. Data were obtained from the National Comprehensive Cancer Network Non-Hodgkin Lymphoma...

journal_title：Leukemia & lymphoma

authors： Abou-Nassar KE,Vanderplas A,Friedberg JW,Abel GA,Niland J,Rodriguez MA,Czuczman MS,Millenson M,Crosby A,Gordon LI,Zelenetz AD,Kaminski M,Lacasce AS

更新日期：2013-10-01 00:00:00

abstract：:Acute promyelocytic leukemia (APL) is characterized by a unique hemorrhagic syndrome, disseminated intravascular coagulation, and the association with the specific (15;17 chi q22-23:q12-21) translocation, which disrupts the retinoic acid receptor alpha (RARA) and the promyelocytic leukemia (PML) genes. The t(15;17) le...

journal_title：Leukemia & lymphoma

authors： Brunel V,Lafage-Pochitaloff M,Alcalay M,Pelicci PG,Birg F

更新日期：1996-07-01 00:00:00

abstract：:We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains of chromosome 1q (+1q). We retrospectively identified 95 patients, 21% having +1q. For patients with +1q, the overall response rate to induction was 85%, with 40% having...

journal_title：Leukemia & lymphoma

authors： Shah GL,Landau H,Londono D,Devlin SM,Kosuri S,Lesokhin AM,Lendvai N,Hassoun H,Chung DJ,Koehne G,Jhanwar SC,Landgren O,Levine R,Giralt SA

更新日期：2017-08-01 00:00:00

abstract：:Little is known about disparities in myelodysplastic syndromes (MDS). We performed a retrospective chart review of patients with MDS (n = 252) evaluated at the University of Maryland Greenebaum Cancer Center between 2000 and 2010. The median age at diagnosis was 65 years, which was lower than the median age of 76 year...

journal_title：Leukemia & lymphoma

authors： Zandberg DP,Hendrick F,Vannorsdall E,Bierenbaum J,Tidwell ML,Ning Y,Zhao XF,Davidoff AJ,Baer MR

更新日期：2013-02-01 00:00:00

abstract：:The standard CHOP regimen may cure 30-40% of patients with advanced aggressive non-Hodgkin's lymphoma (ANHL). Mitoxantrone is an anthracenedione, which is active in NHL and its toxicity profile may be more favorable than doxorubicin with respect to alopecia, mucositis and cardiotoxicity. This study was designed to com...

journal_title：Leukemia & lymphoma

authors： Pangalis GA,Vassilakopoulos TP,Michalis E,Roussou P,Vrakidou E,Repousis P,Angelopoulou MK,Siakantaris MP,Korantzis J,Symeonidis A,Grigorakis V,Stefanoudakis E,Stamatellou M,Bourantas KL,Kalmantis T,Christopoulos G,Kokkini

更新日期：2003-04-01 00:00:00

abstract：:There are limited data regarding the role of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET-CT) scanning in primary mediastinal B-cell lymphoma (PMBL). We analyzed 28 patients with PMBL treated with chemotherapy, of whom 25 (89%) also received rituximab and 17 (61%) radiotherap...

journal_title：Leukemia & lymphoma

authors： Cheah CY,Hofman MS,Seymour JF,Ritchie DS,Dickinson M,Wirth A,Prince HM,Wolf M,Januszcewicz EH,Carney DA,Herbert KE,Harrison SJ,Burbury KL,Tam CS

更新日期：2015-01-01 00:00:00

abstract：:We conducted a phase I clinical trial of a new combination of fludarabine and paclitaxel in which 19 patients with histologically confirmed recurrent low-grade non-Hodgkin's lymphoma (NHL) were treated at five dose levels. Fludarabine was administered intravenously by bolus for 5 days and paclitaxel was given by intra...

journal_title：Leukemia & lymphoma

authors： Younes A,Rodriguez MA,McLaughlin P,North L,Sarris AH,Pate O,Hagemeister FB,Romaguera J,Preti A,Bachier C,Cabanillas F

更新日期：1997-06-01 00:00:00

abstract：:Nearly ten years of research on the feasibility of specific immunotherapy targeting the junctional regions of BCR-ABL has considerably increased our knowledge of which MHC alleles might present BCR-ABL peptides, yet has failed to provide us with definite proof of appropriate processing of the hybrid oncoprotein into s...

journal_title：Leukemia & lymphoma

authors： Leeksma OC,Kessler JH,Huijbers IJ,Ten Bosch GJ,Melief CJ

更新日期：2000-06-01 00:00:00

abstract：:Until recently, combination chemotherapy with melphalan and prednisone (MP) has remained the most widely accepted treatment option for elderly patients with multiple myeloma (MM). However, since the availability of new and more active drugs, several groups have compared in several phase III trials the efficacy and saf...

journal_title：Leukemia & lymphoma

authors： De La Rubia J,Sanz MA

更新日期：2011-01-01 00:00:00

abstract：:Central to discovering novel approaches to treating leukemias and lymphomas is a clear understanding of the signaling networks which lead to unchecked cell cycle progression, proliferation, and survival. Cyclic-adenosine monophosphate (cAMP) responsive element-binding protein (CREB) represents a critical integrator of...

journal_title：Leukemia & lymphoma

authors： Mitton B,Cho EC,Aldana-Masangkay GI,Sakamoto KM

更新日期：2011-11-01 00:00:00

abstract：:The management of AF represents a major challenge in patients with CLL, especially in elderly patients with multiple comorbidities who are representative of the majority of patients with CLL. This is especially complex in the case of ibrutinib. Many anticoagulants have potential for pharmacological interaction with ib...

journal_title：Leukemia & lymphoma

authors： Chai KL,Rowan G,Seymour JF,Burbury K,Carney D,Tam CS

更新日期：2017-12-01 00:00:00

abstract：:We describe a 45-year-old female who developed acute myelogenous leukemia (AML) associated with a mediastinal mass. The patient achieved a complete remission accompanied by resolution of the mediastinal mass following intensive chemotherapy alone. A review of the literature disclosed ten AML patients with a mediastina...

journal_title：Leukemia & lymphoma

authors： Chubachi A,Miura I,Takahashi N,Nimura T,Imai H,Miura AB

更新日期：1993-12-01 00:00:00

abstract：:Management of relapsed lymphoma depends upon the variables of chemosensitive disease and successful stem cell mobilization. The microtubule specific agents, paclitaxel and vinorelbine, have efficacy in relapsed lymphoma and can enhance stem cell mobilization. We performed a phase I dose-escalation study of cytarabine ...

journal_title：Leukemia & lymphoma

authors： Lonial S,Arellano M,Hutcherson D,Langston A,Flowers C,Heffner LT,Winton E,Jo Lechowicz M,Waller EK

更新日期：2006-10-01 00:00:00

abstract：:In this study cytogenetic findings have been correlated with prognosis in 78 previously untreated patients with non-Hodgkin's lymphoma (NHL) presenting between 1983 and 1988. The median follow-up was 7 years (range 2-9 years). There was no significant difference in the duration of survival of 33 patients with only abn...

journal_title：Leukemia & lymphoma

authors： Juneja S,Matthews J,Lukeis R,Laidlaw C,Cooper I,Wolf M,Ironside P,Garson OM

更新日期：1997-05-01 00:00:00

abstract：:Abstract The aim of this study was to evaluate the prognostic importance of rituximab and radiotherapy in patients with primary mediastinal large B-cell lymphoma (PMBCL) receiving doxorubicin-containing chemotherapy. Seventy-nine patients with PMBCL received CHOP chemotherapy with (n = 39) or without rituximab (n = 40...

journal_title：Leukemia & lymphoma

authors： Xu LM,Fang H,Wang WH,Jin J,Wang SL,Liu YP,Song YW,Ren H,Zhou LQ,Li YX

更新日期：2013-08-01 00:00:00

abstract：:We report results of a randomized, phase III study of ofatumumab versus physicians' choice treatment in patients with bulky fludarabine-refractory chronic lymphocytic leukemia and explore extended versus standard-length ofatumumab treatment. Patients (79 ofatumumab, 43 physicians' choice) completed a median 6 (ofatumu...

journal_title：Leukemia & lymphoma

authors： Österborg A,Udvardy M,Zaritskey A,Andersson PO,Grosicki S,Mazur G,Kaplan P,Steurer M,Schuh A,Montillo M,Kryachok I,Middeke JM,Kulyaba Y,Rekhtman G,Gorczyca M,Daly S,Chang CN,Lisby S,Gupta I

更新日期：2016-09-01 00:00:00

abstract：:Pulmonary marginal zone lymphoma is a rare disease arising from bronchial-associated lymphoid tissue (BALT). There is limited information on clinical presentation, natural history and treatment of this type of lymphoma. We conducted a retrospective review of patients with biopsy-proven BALT lymphoma treated at our ins...

journal_title：Leukemia & lymphoma

authors： Stefanovic A,Morgensztern D,Fong T,Lossos IS

更新日期：2008-07-01 00:00:00

abstract：:Clofarabine is a good generation purine nucleoside analogue designed to overcome the limitations and to incorporate the best qualities of both cladribine and fludarabine. Clofarabine is thought to work via three mechanisms: inhibition of ribonucleotide reductase; incorporation to DNA; and induction of apoptosis. Given...

journal_title：Leukemia & lymphoma

authors： Kantarjian HM,Jeha S,Gandhi V,Wess M,Faderl S

更新日期：2007-10-01 00:00:00

abstract：:Current therapies for the treatment of malignancies are associated with significant limitations to the hematopoietic system since chemotherapy and radiation therapy do not discriminate between normal and malignant cells. Since bone marrow depression occurs at low to midlethal doses of irradiation, approaches to improv...

journal_title：Leukemia & lymphoma

authors： Zucali JR

更新日期：1994-03-01 00:00:00

abstract：:Ibrutinib increases the risk of atrial fibrillation (AF), but the associated risk factors are not clearly defined. We performed retrospective review of ibrutinib-treated patients in a large academic practice to identify risk factors for new-onset AF. Variables with p-values <.05 in logrank analysis were included as pa...

journal_title：Leukemia & lymphoma

authors： Lentz R,Feinglass J,Ma S,Akhter N

更新日期：2019-06-01 00:00:00

abstract：:Several surveys have defined chronic lymphocytic leukemia (CLL) patients as a high-risk patient population for developing second neoplasms. As possible mechanisms underlying the increased risk of specific second malignancies in CLL patients the immunodeficiency associated with disease is generally proposed. As far as ...

journal_title：Leukemia & lymphoma

authors： Molica S

更新日期：2005-01-01 00:00:00